*ST華昌(300278.SZ):顏華所持公司股份將被司法拍賣240萬股
格隆匯5月24日丨*ST華昌(300278.SZ)公佈,此次將被拍賣的股份為持股5%以上股東顏華所持公司240萬股首發後限售股,佔其所持公司全部股份的5.41%,佔公司總股本的0.42%。
目前拍賣事項尚在公示階段,拍賣結果存在不確定性,公司將持續關注該事項的進展情況,並及時履行信息披露義務。
截至公吿日,顏華持有公司股份數為4435.079萬股,佔公司總股本的7.70%,其中處於質押狀態股份數為4435萬股,佔其所持公司股份的99.998%,其處於司法凍結狀態股份數為4435.079萬股,佔其所持公司股份100%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.